

Manuel Barreiro-de Acosta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/437983/publications.pdf>

Version: 2024-02-01

56
papers

1,716
citations

471509

17
h-index

289244

40
g-index

64
all docs

64
docs citations

64
times ranked

2281
citing authors

#	ARTICLE	IF	CITATIONS
1	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 239-254.	1.3	577
2	Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 13-19.	1.3	167
3	Delphi consensus statement: Quality indicators for Inflammatory Bowel Disease Comprehensive Care Units. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 240-251.	1.3	89
4	Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 762-769.	1.6	82
5	Psychological Factors Are Associated with Changes in the Health-related Quality of Life in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 20, 1.	1.9	79
6	Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1394-1402.	1.9	71
7	Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 756-758.	1.6	69
8	Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 135-142.	3.7	51
9	Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation. <i>Digestive Diseases and Sciences</i> , 2017, 62, 481-490.	2.3	43
10	Does Smoking Influence Crohn's Disease in the Biologic Era? The TABACROHN Study. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 23-29.	1.9	42
11	Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2885.	2.4	38
12	Ulcerative colitis in northern Portugal and Galicia in Spain. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 1227-1238.	1.9	27
13	Characteristics and Progression of Preclinical Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1459-1466.	4.4	27
14	Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3075-3084.	2.3	26
15	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) y de la Confederación de Asociaciones de Enfermedad de Crohn y Colitis Ulcerosa (ACCU) para el manejo de los aspectos psicológicos en la enfermedad inflamatoria intestinal. <i>Gastroenterología y Hepatología</i> , 2018, 41, 118-127.	0.5	26
16	Inflammatory bowel disease integral care units: Evaluation of a nationwide quality certification programme. The GETECCU experience. <i>United European Gastroenterology Journal</i> , 2021, 9, 766-772.	3.8	22
17	EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481984703.	3.2	18
18	How do psychological variables influence coping strategies in inflammatory bowel disease?. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e219-e226.	1.3	17

#	ARTICLE	IF	CITATIONS
19	Role of Quality of Life as Endpoint for Inflammatory Bowel Disease Treatment. International Journal of Environmental Research and Public Health, 2021, 18, 7159.	2.6	17
20	Perioperative management and early complications after intestinal resection with ileocolonic anastomosis in Crohn's disease: analysis from the PRACTICROHN study. Gastroenterology Report, 2019, 7, 168-175.	1.3	16
21	A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine. Journal of Gastrointestinal and Liver Diseases, 2011, 20, 247-53.	0.9	16
22	Influence of alexithymia on health-related quality of life in inflammatory bowel disease: Are there any related factors?. Scandinavian Journal of Gastroenterology, 2012, 47, 445-453.	1.5	15
23	Recomendaciones del Grupo Espaol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 1: epidemiologaa, diagnstico y pronstico. Gastroenterologaa Y Hepatologaa, 2019, 42, 568-578.	0.5	11
24	Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu. Journal of Clinical Medicine, 2021, 10, 4402.	2.4	10
25	COVID-19-related personal product shortages are associated with psychological distress in people living with gastrointestinal disorders: A cross-sectional survey. Neurogastroenterology and Motility, 2022, 34, e14198.	3.0	9
26	NOD2/CARD15: geographic differences in the Spanish population and clinical applications in Crohn's disease. Revista Espanola De Enfermedades Digestivas, 2010, 102, 321-6.	0.3	9
27	Pouchitis: Treatment dilemmas at different stages of the disease. United European Gastroenterology Journal, 2020, 8, 256-262.	3.8	8
28	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. Journal of Clinical Medicine, 2021, 10, 2914.	2.4	8
29	SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project. Gastroenterologaa Y Hepatologaa, 2022, 45, 737-741.	0.5	8
30	Extending the Common Sense Model to Explore the Impact of the Fear of COVID-19 on Quality of Life in an International Inflammatory Bowel Disease Cohort. Journal of Clinical Psychology in Medical Settings, 2022, 29, 678-688.	1.4	8
31	Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry. Journal of Clinical Medicine, 2022, 11, 421.	2.4	8
32	Recomendaciones del Grupo Espaol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la reservoritis en la colitis ulcerosa. Parte 2: Tratamiento. Gastroenterologaa Y Hepatologaa, 2020, 43, 649-658.	0.5	7
33	Targeted 1H NMR metabolomics and immunological phenotyping of human fresh blood and serum samples discriminate between healthy individuals and inflammatory bowel disease patients treated with anti-TNF. Journal of Molecular Medicine, 2021, 99, 1251-1264.	3.9	7
34	The impact of the coronavirus (COVID-19) pandemic on individuals with gastrointestinal disorders: A protocol of an international collaborative study. Journal of Psychosomatic Research, 2021, 148, 110561.	2.6	7
35	Resumption of activity in gastroenterology departments. Recommendations by SEPD, AEEH, GETECCU and AEG. Revista Espanola De Enfermedades Digestivas, 2020, 112, 397-411.	0.3	7
36	Clinical applications of NOD2/CARD15 mutations in Crohn's disease. Acta Gastroenterologica Latinoamericana, 2007, 37, 49-54.	0.1	7

#	ARTICLE	IF	CITATIONS
37	Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry. <i>Journal of Crohn's and Colitis</i> , 2021, , .	1.3	6
38	Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path toward the implementation of telemedicine in Spain?. <i>GastroenterologÅa Y HepatologÅa</i> , 2022, 45, 697-705.	0.5	5
39	Clinical status, quality of life, and work productivity in CrohnÅ's disease patients after one year of treatment with adalimumab. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016, 109, 122-129.	0.3	5
40	Recommendations of the Spanish Working Group on CrohnÅ™s Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 1: Epidemiology, diagnosis and prognosis. <i>GastroenterologÅa Y HepatologÅa (English Edition)</i> , 2019, 42, 568-578.	0.1	4
41	COVID-19 and inflammatory bowel disease: Questions arising from patient care and follow-up during the initial phase of the pandemic (FebruaryÅ€April 2020). <i>GastroenterologÅa Y HepatologÅa (English) Tj ETQq1 1 0.7843144gBT /Overlock 30 Tf 50 45</i>	0.1	4
42	Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients. <i>Frontiers in Medicine</i> , 2022, 9, 823900.	2.6	4
43	Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of CrohnÅ™s Disease Severity. <i>Biomedicines</i> , 2022, 10, 727.	3.2	4
44	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on pouchitis in ulcerative colitis. Part 2: Treatment. <i>GastroenterologÅa Y HepatologÅa (English) Tj ETQq0 0 0 rgBT /Overlock 30 Tf 50 45</i>	0.1	4
45	Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2021, 53, 1571-1579.	0.9	3
46	Increased use of healthcare resources during the preclinical period of inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2021, 53, 927-930.	0.9	3
47	Adherence improvement in patients with ulcerative colitis: a multidisciplinary consensus document. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, , .	0.3	3
48	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) and the Association of Crohn's Disease and Ulcerative Colitis Patients (ACCU) in the management of psychological problems in Inflammatory Bowel Disease patients. <i>GastroenterologÅa Y HepatologÅa (English Edition)</i> , 2018, 41, 118-127.	0.1	2
49	Letter: predictors of severe disease in ulcerative colitis - the same or different in CrohnÅ€s disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 1120-1121.	3.7	1
50	The natural history of extraintestinal manifestations after surgery in inflammatory bowel disease: Never give up!. <i>United European Gastroenterology Journal</i> , 2021, 9, 748-749.	3.8	1
51	Psychosocial impact of the covid-19 pandemic on patients with inflammatory bowel disease in spain. A post lockdown reflection. <i>GastroenterologÅa Y HepatologÅa</i> , 2021, , .	0.5	1
52	Radon exposure and inflammatory bowel disease in a radon prone area. <i>Revista Espanola De Enfermedades Digestivas</i> , 2021, , .	0.3	1
53	Comment to Å€œBiosimilars: The viewpoint of Italian patients with inflammatory bowel diseaseÅ€: <i>Digestive and Liver Disease</i> , 2020, 52, 1302-1303.	0.9	0
54	Risk of Depression During the Natural History of Inflammatory Bowel Disease: The Phantom Menace. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e99-e100.	1.9	0

#	ARTICLE	IF	CITATIONS
55	¿Debemos investigar enfermedades respiratorias en pacientes con enfermedad inflamatoria intestinal?. Archivos De Bronconeumologia, 2020, 56, 481-482.	0.8	0
56	Management and long-term outcomes of Crohn's disease complicated with enterocutaneous fistula: ECUFIT study from GETECCU. Journal of Crohn's and Colitis, 2022, , .	1.3	0